News

Kalydeco (ivacaftor), an approved therapy for cystic fibrosis (CF) patients with a specific mutation, improves insulin secretion in those with CF-related diabetes, researchers led by Ronald Rubenstein, MD, with the Children’s Hospital of Philadelphia, found. The mechanism underlying this benefit, however, remains unknown. The results were presented today at the 30th Annual North American…

In a talk presented today, Charles Esther Jr., MD, PhD, from UNC Chapel Hill, identified the loss of airway hydration as the first triggering factor in young children with cystic fibrosis (CF). The talk, titled “Mucus Dehydration as the Initiating Defect in Early CF Airways Disease,” was presented at the 30th Annual…

Among people with rare mutations in the CFTR gene, the gene defective in cystic fibrosis (CF), studies are needed to map down which patients may benefit from CFTR potentiators, such as Kalydeco (ivacaftor), or CFTR correctors. In this way, researchers will also be able to identify those in need…

Liver disease in cystic fibrosis (CF) patients needs to be detected much earlier, but early detection is increasingly likely as research interest in severe forms of the condition has grown. That was the message relayed during a talk by Dr. Daniel Leung of Baylor College Of Medicine in Texas, presented…

Recommendations by the Cystic Fibrosis Foundation (CFF) on enternal tube feeding for patients were supported by Jillian Sullivan, MD, from the University of Vermont Children’s Hospital today at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida. Sullivan’s presentation,“Role of the Gastroenterologist in Enteral Tube Feedings,” was part of a symposium…

Promising results of preclinical studies evaluating the effectiveness of SYGN113 to treat bacterial biofilms in the lungs of patients with cystic fibrosis (CF), and of SYGN303 to treat the gastrointestinal consequences of the disease, were presented at the North American Cystic Fibrosis Conference (NACFC) now taking place in Orlando. Bacterial biofilms are…

Abnormal mucus clearance in patients with cystic fibrosis (CF) may be improved with specific treatments, but despite intense research on the subject, there are many unanswered questions about how atypical mucus contributes to the disease and how to best improve the problem. Researchers debated the issue in three discussions at a…

In today’s symposium “Growing Older With CF” at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, Cathy Chacon, RN, from National Jewish Health, presented a discussion about integrating routine screenings into overall healthcare for aging CF patients. The session was titled “Recommended Screenings for Adults with CF.”…

In a recent symposium, scientists discussed the increased importance of physical therapy in addressing cystic fibrosis-associated muscle impairments and urinary incontinence. The presentation, titled “Posture, Pelvic Floor & Pistons: A Look Beyond ‘Kegels’ to Treat Urinary Incontinence,” was given today at the Symposium “Growing Older With CF” at the 30th…

Tai chi, taught either in face-to-face home sessions or using internet-based video calls, improved ease of breathing and posture in cystic fibrosis (CF) patients who participated in a trial. Findings also showed that patients felt calmer and less stressed, which likely contributed to the ease of breathing. The study,…